TriangleNCT00652132 · CITED IN SOURCE DOCUMENTS
Cisplatin With or Without Sodium Thiosulfate in Treating Young Patients With Stage I, II, or III Childhood Liver Cancer
An NCI or FDA source cites this study. A citation does not establish that it applies to an individual diagnosis.
- Phase
- PHASE3
- Status at capture
- COMPLETED
- Registry last update
- 2018-05-29
RATIONALE: Drugs used in chemotherapy, such as cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Chemoprotective drugs, such as sodium thiosulfate, may protect normal cells from the side effects of chemotherapy. It is not yet known whether giving sodium thiosulfate is effective in reducing hearing damage caused by cisplatin in treating young patients with liver cancer. PURPOSE: This randomized phase III trial is studying how well sodium thiosulfate works to decrease hearing loss caused by cisplatin in treating young patients with stage I, stage II, or stage III childhood liver cancer.
Open the original ClinicalTrials.gov record → · Download preserved record
What did the study report?
Outcomes, safety and baseline populations are separate source sections. Quality-of-life measures appear under their original outcome titles.
No posted result sections were captured. Registered plans do not establish that a treatment works.
Who could take part
- eligibility Criteria
- Inclusion Histologically confirmed newly diagnosed hepatoblastoma * Standard risk hepatoblastoma (Pretext I,II,III) * Age ≤ 18 years and \> 1 month * Written informed consent and national/local ethics committee and regulatory approval * Centre/country willing and able to organise audiometry at the minimum required quality standard and to provide the contact details of the Consultant Audiologist or Ear Nose and Throat Surgeon who will take the responsibility for seeing that this is done * Ability to comply with requirements for submission of material for central review * For females of child-bearing potential, a negative pregnancy test prior to study treatment is required. * Any patient who is of reproductive age should agree to use adequate contraception for the duration of the trial. Exclusion: High risk hepatoblastoma * Hepatocellular carcinoma * Treatment starting more than 15 days from written biopsy report * Abnormal renal function * Any previous chemotherapy * Recurrent disease * Previous hypersensitivity to STS * Patient unable to follow the protocol for any reason
- healthy Volunteers
- false
- maximum Age
- 18 Years
- minimum Age
- 1 Month
- sex
- ALL
- std Ages
- CHILD
- ADULT
Treatment arms and interventions
- arm Groups
- description
- Neoadjuvant and adjuvant cisplatin: patients receive cisplatin IV over 6 hours on day 1. Treatment repeats every 2 weeks for 4 courses. Patients with progressive disease after course 4 are taken off study. Patients without evidence of disease progression proceed to surgery. Beginning within 3 weeks after surgery, patients receive cisplatin IV over 6 hours on day 1. Treatment repeats every 2 weeks for 2 courses in the absence of disease progression or unacceptable toxicity.
- intervention Names
- Drug: cisplatin
- label
- Arm I (cisplatin)
- type
- ACTIVE_COMPARATOR
- description
- Neoadjuvant and adjuvant cisplatin and sodium thiosulphate (STS): patients receive cisplatin IV over 6 hours and sodium thiosulphate IV over 15 minutes (beginning 6 hours after completion of cisplatin) on day 1. Treatment repeats every 2 weeks for 4 courses. Patients with progressive disease after course 4 are taken off study. Patients without evidence of disease progression proceed to surgery. Beginning within 3 weeks after surgery, patients receive cisplatin IV over 6 hours and sodium thiosulphate IV over 15 minutes (as in neoadjuvant therapy) on day 1. Treatment repeats every 2 weeks for 2 courses in the absence of disease progression or unacceptable toxicity.
- intervention Names
- Drug: cisplatin
- Drug: sodium thiosulfate
- label
- Arm II (cisplatin + STS)
- type
- EXPERIMENTAL
- interventions
- arm Group Labels
- Arm I (cisplatin)
- Arm II (cisplatin + STS)
- name
- cisplatin
- type
- DRUG
- arm Group Labels
- Arm II (cisplatin + STS)
- name
- sodium thiosulfate
- type
- DRUG
Study design
- allocation
- RANDOMIZED
- intervention Model
- PARALLEL
- masking Info
- masking
- NONE
- primary Purpose
- TREATMENT
Enrollment
- count
- 116
- type
- ACTUAL
Registered outcome plans (not posted results)
- primary Outcomes
- description
- To investigate if the administration of sodium thiosulfate simultaneously with the administration of Cisplatin significantly reduces the hearing impairment
- measure
- Rate of Brock grade ≥ 1 hearing loss
- time Frame
- End of trial treatment or at an age of 3.5 years, whichever is later
- secondary Outcomes
- description
- Defined as: Complete response (CR): no evidence of disease and normal serum AFP value (for age). Partial response (PR): any tumour volume shrinkage associated with a decreasing serum AFP value, \> 1 log below the original measurement. Stable disease (SD): no tumour volume change and no change, or \< 1 log fall of the serum AFP concentration. Progressive disease (PD): unequivocal increase in 1 or more dimensions and/or any unequivocal increase of the serum AFP concentration (three successive 1-2 weekly determinations) even without clinical (physical and/or radiological) evidence of tumour re-growth.
- measure
- Response to preoperative chemotherapy
- time Frame
- Following completion of preoperative chemotherapy
- description
- Total macroscopic removal of the tumour as reported by the surgeon and pathologist. In case of any doubt the lack of residual tumour must be confirmed with imaging studies performed
- measure
- Complete resection
- time Frame
- Within 2 weeks after surgery.
- description
- Lack of evidence of residual disease and normal (for age) alpha-foetal protein (AFP). To establish a complete remission all of the following requirements must be fulfilled: * No evidence of tumour intra-abdominally: negative abdominal (including hepatic) ultrasound or CT scan or Magnetic resonance imaging * No evidence of metastases: clear chest X-ray (PA and lateral) for non-metastatic patients. (Normal lung CT scan for patients with lung metastasis at diagnosis, who are high-risk by definition and not treated according to SIOPEL 6). * Serum AFP level either normal or compatible with age for at least 4 weeks after normalisation.
- measure
- Complete remission
- time Frame
- End of trial treatment
- description
- Calculated from the time of randomisation to the first of the following events: progression, relapse, secondary primary malignancy or death.
- measure
- Event-free survival (EFS)
- time Frame
- Until first event or up to 5 years
- description
- Calculated from the time of randomisation to death.
- measure
- Overall survival (OS)
- time Frame
- Until event or up to 5 years
- description
- Adverse drug reactions are defined as adverse events, which are possibly, probably or definitely related to the trial treatment. They will be assessed according to NCI CTCAE v 3.0.
- measure
- Toxicity as graded by CTCAE v 3.0
- time Frame
- 30 days post treatment
- description
- By clearance method either EDTA, iohexol or inulin.
- measure
- Long-term renal clearance
- time Frame
- Until event or up to 5 years
- description
- The feasibility of central review
- measure
- Feasibility of central audiology review
- time Frame
- End of trial treatment or at an age of 3.5 years, whichever is later
Full study description
- brief Summary
- RATIONALE: Drugs used in chemotherapy, such as cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Chemoprotective drugs, such as sodium thiosulfate, may protect normal cells from the side effects of chemotherapy. It is not yet known whether giving sodium thiosulfate is effective in reducing hearing damage caused by cisplatin in treating young patients with liver cancer. PURPOSE: This randomized phase III trial is studying how well sodium thiosulfate works to decrease hearing loss caused by cisplatin in treating young patients with stage I, stage II, or stage III childhood liver cancer.
- detailed Description
- OBJECTIVES: Primary * To assess the efficacy of sodium thiosulfate (STS) to reduce the hearing impairment caused by cisplatin chemotherapy. Secondary * To carefully monitor any potential impact of STS on response to cisplatin and survival. * To assess the short- and long-term tolerability of the combination of STS and cisplatin * To prospectively evaluate and validate biological, radiological and pathological features of standard-risk hepatoblastoma for future risk adapted management * To investigate the effect of STS on the formation of cisplatin-DNA adducts. * To prospectively collect patient DNA specifically for the analysis of possible genetic factors that may contribute to the development of treatment-related ototoxicity and nephrotoxicity OUTLINE: This is a multicenter study. Patients are stratified according to country, median age (\< 15 months vs ≥ 15 months), and PRETEXT tumor classification (I vs II vs III). Patients are randomized to 1 of 2 treatment arms. * Arm I (Neoadjuvant and adjuvant cisplatin): Patients receive cisplatin IV over 6 hours on day 1. Treatment repeats every 2 weeks for 4 courses. Patients with progressive disease after course 4 are taken off study. Patients without evidence of disease progression proceed to surgery. Beginning within 3 weeks after surgery, patients receive cisplatin IV over 6 hours on day 1. Treatment repeats every 2 weeks for 2 courses in the absence of disease progression or unacceptable toxicity. * Arm II (Neoadjuvant and adjuvant cisplatin and sodium thiosulphate): Patients receive cisplatin IV over 6 hours and sodium thiosulphate IV over 15 minutes (beginning 6 hours after completion of cisplatin) on day 1. Treatment repeats every 2 weeks for 4 courses. Patients with progressive disease after course 4 are taken off study. Patients without evidence of disease progression proceed to surgery. Beginning within 3 weeks after surgery, patients receive cisplatin IV over 6 hours and sodium thiosulphate IV over 15 minutes (as in neoadjuvant therapy) on day 1. Treatment repeats every 2 weeks for 2 courses in the absence of disease progression or unacceptable toxicity. Patients undergo blood collection and tumor biopsies periodically for biological and pharmacological studies consisting of biomarker analysis, gene expression profiling, IHC, proteomic analysis, and gene rearrangement analysis. Patients undergo auditory evaluations at baseline, and at the completion of study treatment or at an age of at least 3.5 years to measure ototoxicity and hearing impairment. After completion of study treatment, patients are followed periodically for at least 5 years.
Source references
- references
- citation
- Brock PR, Maibach R, Childs M, Rajput K, Roebuck D, Sullivan MJ, Laithier V, Ronghe M, Dall'Igna P, Hiyama E, Brichard B, Skeen J, Mateos ME, Capra M, Rangaswami AA, Ansari M, Rechnitzer C, Veal GJ, Covezzoli A, Brugieres L, Perilongo G, Czauderna P, Morland B, Neuwelt EA. Sodium Thiosulfate for Protection from Cisplatin-Induced Hearing Loss. N Engl J Med. 2018 Jun 21;378(25):2376-2385. doi: 10.1056/NEJMoa1801109.
- pmid
- 29924955
- type
- DERIVED
Source notices and limitations
Discovery and provenance
- release id
- ctgov-registry-7ad944f6deaf1f5cd6122126
- edge id
- nct-edge-cd2e50cee9d05dbcec3d
- requested nct id
- NCT00652132
- primary nct id
- NCT00652132
- source kind
- fda_spl_label
- source record id
- 889accaa-7f62-4da4-84ea-80ecfb144209
- source file sha256
- 424ccf5bc67db0a96ee2c35ed913dd5894642716182773d81ca19cdfb9ba32f3
- payload sha256
- 9ac9ec4b2e8300a058a6c38ee061dd576efde73e94f60be21d102ccab36efc76
- payload
- application numbers
- NDA212937
- clinical indication matching status
- not_inferred
- end exclusive
- true
- id
- nct-edge-cd2e50cee9d05dbcec3d
- link basis
- explicit_NCT_identifier_in_acquired_source
- nct id
- NCT00652132
- occurrences
- context exact
- acy of PEDMARK in reducing the risk of cisplatin-associated ototoxicity was evaluated in two multicenter studies: SIOPEL 6 and COG ACCL0431. SIOPEL 6 SIOPEL 6 (NCT00652132) was a multicenter, randomized, controlled, open-label study. Eligible patients were between 1 month and 18 years of age and were receiving cisplatin-based che
- end
- 200
- exact text
- NCT00652132
- start
- 189
- offset unit
- unicode_code_points
- source file
- /tmp/cancer-full-research/indications/raw/labels-00500.json
- source file sha256
- 424ccf5bc67db0a96ee2c35ed913dd5894642716182773d81ca19cdfb9ba32f3
- source json pointer
- /results/6/clinical_studies/0
- source kind
- fda_spl_label
- source record id
- 889accaa-7f62-4da4-84ea-80ecfb144209
- source string basis
- parsed_JSON_string_unmodified
- source string sha256
- ec158ae2a0e8b5f34d64ec32c6df01036d036e19cf2990fe1720355fb17b1c68
- spl effective time
- 20251027
- spl set id
- f98c7076-2a7b-4fd7-ab90-eed5e9137bae
- release id
- ctgov-registry-7ad944f6deaf1f5cd6122126
- edge id
- nct-edge-edef01c7a6cef1c2ff92
- requested nct id
- NCT00652132
- primary nct id
- NCT00652132
- source kind
- nci_explicit_reference_or_link
- source record id
- Source null
- source file sha256
- 8e2f0655eba965520d5aba7845c5f4b0d5039a99f3805eb4dac6550369393754
- payload sha256
- 856f21249457b5db2c203c07550b89c2ca55b66a079798181af8f3b831ac0389
- payload
- clinical indication matching status
- not_inferred
- end exclusive
- true
- id
- nct-edge-edef01c7a6cef1c2ff92
- link basis
- explicit_NCT_identifier_in_acquired_source
- nct id
- NCT00652132
- occurrences
- context exact
- ncology Group <a href="/clinicaltrials/NCT00716976">ACCL0431 [NCT00716976]</a> and International Childhood Liver Tumour Strategy Group <a href="/clinicaltrials/NCT00652132">SIOPEL-6 [NCT00652132]</a>), sodium thiosulfate demonstrated efficacy in preventing cisplatin-induced hearing loss.[<a href="#cit/section_11.14">14</a>,<a hre
- end
- 1220236
- exact text
- NCT00652132
- start
- 1220225
- context exact
- /clinicaltrials/NCT00716976">ACCL0431 [NCT00716976]</a> and International Childhood Liver Tumour Strategy Group <a href="/clinicaltrials/NCT00652132">SIOPEL-6 [NCT00652132]</a>), sodium thiosulfate demonstrated efficacy in preventing cisplatin-induced hearing loss.[<a href="#cit/section_11.14">14</a>,<a href="#cit/section_11.15">
- end
- 1220259
- exact text
- NCT00652132
- start
- 1220248
- offset unit
- unicode_code_points
- source file
- /tmp/cancer-full-research/nci/raw/a1f488590c9b8fd864.html
- source file sha256
- 8e2f0655eba965520d5aba7845c5f4b0d5039a99f3805eb4dac6550369393754
- source json pointer
- Source null
- source kind
- nci_explicit_reference_or_link
- source record id
- Source null
- source retrieved at
- 2026-09-09T23:21:37.900601+00:00
- source string basis
- UTF-8_text_with_universal_newline_translation
- source string sha256
- a399e2129082d5ab2ef6ddc2c404eee9ea85e374555e618ef2db7feb98891c8b
- source title
- Late Effects of Treatment for Childhood Cancer (PDQ®)–Health Professional Version
- source update dates
- context
- Updated: April 14, 2025
- datetime
- 2025-04-14T12:00:00Z
- display
- April 14, 2025
Preserved source evidence · Not medical advice